DIABETIC RETINOPATHY: THE ROLE OF LIPOPROTEIN(A)
Completed
- Conditions
- diabetic retinopathy10047060
- Registration Number
- NL-OMON46153
- Lead Sponsor
- Oogziekenhuis Rotterdam
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 40
Inclusion Criteria
Age >= 18 years
Informed consent
Diabetic retinopathy
Exclusion Criteria
Other retinal pathology
Glaucoma
Study & Design
- Study Type
- Observational invasive
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method <p>Lp(a) concentration.</p><br>
- Secondary Outcome Measures
Name Time Method <p>Molecular characteristics Lp(a).</p><br>
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways link elevated lipoprotein(a) levels to diabetic retinopathy progression in observational studies?
How does lipoprotein(a) concentration correlate with anti-VEGF treatment outcomes in diabetic retinopathy patients?
Are genetic variants in LPA gene expression predictive of diabetic retinopathy severity or response to lipid-lowering therapies?
What adverse events are associated with lipoprotein(a)-targeting interventions in ophthalmic clinical trials?
How do PCSK9 inhibitors or antisense oligonucleotides compare to standard-of-care for managing Lp(a)-related diabetic retinopathy risk?